TY - JOUR
T1 - Immune Checkpoint Blockade for Metastatic Uveal Melanoma
T2 - Re-Induction following Resistance or Toxicity
AU - on behalf of the German Dermatologic Cooperative Oncology Group (DeCOG Committee Ocular Melanoma)
AU - Koch, Elias A.T.
AU - Petzold, Anne
AU - Wessely, Anja
AU - Dippel, Edgar
AU - Gesierich, Anja
AU - Gutzmer, Ralf
AU - Hassel, Jessica C.
AU - Haferkamp, Sebastian
AU - Kähler, Katharina C.
AU - Knorr, Harald
AU - Kreuzberg, Nicole
AU - Leiter, Ulrike
AU - Loquai, Carmen
AU - Meier, Friedegund
AU - Meissner, Markus
AU - Mohr, Peter
AU - Pföhler, Claudia
AU - Rahimi, Farnaz
AU - Schadendorf, Dirk
AU - Schell, Beatrice
AU - Schlaak, Max
AU - Terheyden, Patrick
AU - Thoms, Kai Martin
AU - Schuler-Thurner, Beatrice
AU - Ugurel, Selma
AU - Ulrich, Jens
AU - Utikal, Jochen
AU - Weichenthal, Michael
AU - Ziller, Fabian
AU - Berking, Carola
AU - Heppt, Markus V.
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
AB - Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
UR - http://www.scopus.com/inward/record.url?scp=85122935638&partnerID=8YFLogxK
U2 - 10.3390/cancers14030518
DO - 10.3390/cancers14030518
M3 - Journal articles
AN - SCOPUS:85122935638
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 3
M1 - 518
ER -
